RecruitingRecruiting
A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
NCT07684157 · Jacobio Pharmaceuticals Co., Ltd.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JAB-8263 in Patients With Active Rheumatoid Arthritis
About this study
This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.
Eligibility criteria
Inclusion Criteria:
1. Age ≥18 years old and \<75 years old at the time of signing the informed consent form, regardless of gender;
2. Active rheumatoid arthritis, ESR or C-reactive protein\> upper limit of normal
3. Meets the 2010 American College of Rheumatology ACR/EULAR RA classification standards
4. Participants have recovered from adverse reactions to previous antirheumatic treatment.
Exclusion Criteria:
1. Use of topical glucocorticoids within 2 weeks before the first dose of investigational product or have received epidural, intraarticular, intramuscular, oral or intravenous glucocorticoids within 4 weeks, and do not use adrenocorticotropin;
2. Use of NSAIDs within 1 week before first dose of investigational product
3. Known or suspected allergies to the investigational product or any of its components;
4. Current active shingles virus infection, including shingles or herpes simplex types 1 and 2 (confirmed by physical examination and medical history); participants had a history of severe herpes infection, including any disseminated disease, shingles in multiple skin areas, herpes encephalitis, ocular herpes, or recurrent shingles (2 episodes greater than or equal to 2 episodes within 2 years);
5. Have evidence of active tuberculosis (TB) or have previously had evidence of active TB and have not received appropriate documented treatment;
Study design
Enrollment target: 32 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-07-23
Estimated completion: 2027-12-31
Last updated: 2026-09-28
Interventions
Drug: JAB-8263Drug: JAB-8263
Primary outcomes
- • Evaluate the overall safety and tolerability of JAB-8263 (Up to approximately 12 weeks)
Sponsor
Jacobio Pharmaceuticals Co., Ltd. · industry
Contacts & investigators
ContactJun Yang Jun Project Director · contact · clinicaltrials@jacobiopharma.com · 86 010-05615464
All locations (1)
Beijing HospitalRecruiting
Beijing, Beijing Municipality, China